
Ramsey-Goldman discussed how the lupus field has shifted from her earlier career.

Ramsey-Goldman discussed how the lupus field has shifted from her earlier career.

ACR 2025 research shows polygenic risk scores correlate with specific SLE phenotypes, highlighting potential applications for clinical risk assessment.

At ACR 2025, Dapas discusses how polygenic risk scores link genetic risk to SLICC criteria, advancing precision medicine in systemic lupus erythematosus.

Ramsey-Goldman emphasized the importance of QoL in lupus, looking beyond disease scores.

Ramsey-Goldman discussed the potential of NAC for treating systemic lupus erythematosus.

Khasru discussed the potential of adMSCs to improve outcomes in knee osteoarthritis.

Cuda also discussed further research she'd like to do with cognition and SLE.

Cuda discussed the potential of the NIH toolbox to easily assess cognitive effects in clinical trials.

Mease discussed the latest updates on bimekizumab, sonelokimab, and izokibep at ACR Convergence 2025.

Telitacicept significantly alleviates Sjögren disease symptoms over 48 weeks, outperforming placebo with a favorable safety profile in a phase 3 trial.

In long-term follow-up of KEEPsAKE 1 and 2, risankizumab maintained joint, skin, pain, and axial responses in patients with PsA through 244 weeks.

However, a notable higher rate of treatment-related adverse events warrants caution.

Sonelokimab meets ACR50 primary endpoint in a phase 2 trial.